Huntington's Disease Market Report 2026

Huntington's Disease Market Overview

• Huntington's Disease market size has reached to $0.55 billion in 2025 • Expected to grow to $1.22 billion in 2030 at a compound annual growth rate (CAGR) of 17.5% • Growth Driver: Rising Neurological Disorders Fueling The Growth Of The Market Due To Increasing Diagnosis And Aging Population • Market Trend: Development Of Oral Small Molecule Drugs Driving Innovation In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Huntington's Disease Market?

Huntington's disease is a rare, inherited neurodegenerative disorder that causes the progressive breakdown of nerve cells in the brain, leading to uncontrolled movements, cognitive decline, and emotional disturbances. It is caused by a genetic mutation in the HTT gene and typically appears in mid-adulthood. The main treatment types for huntington's disease include symptomatic therapy, disease-modifying therapy, and other treatment types. Symptomatic therapy focuses on managing symptoms such as movement disorders, psychiatric issues, and cognitive decline without affecting disease progression. The disease is diagnosed using various methods, including magnetic resonance imaging (MRI), computed tomography (CT) scans, genetic testing, and other diagnostic techniques. Drugs are administered through different routes, such as oral, parenteral, and other methods. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies and are used by various end users, including hospitals, home care, specialty clinics, and other healthcare facilities.

What Is The Huntington's Disease Market Growth Forecast?

The huntington's disease market size is expected to see rapid growth in the next few years. It will grow to $1.22 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to advancements in gene therapy and rna-based treatments, rising investment in rare disease research, expanding clinical pipeline for disease-modifying therapies, growing focus on early intervention strategies, increasing support from patient advocacy organizations. Major trends in the forecast period include increasing focus on disease-modifying and gene silencing therapies, growing adoption of genetic testing for early and accurate diagnosis, rising emphasis on multidisciplinary symptom management approaches, expansion of clinical trials targeting neurodegenerative disorders, increasing patient-centric care models and home-based management.

Global Huntington's Disease Market Segmentation

1) By Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, Other Treatment Types 2) By Diagnosis: Magnetic Resonance Imaging (MRI), Genetic Testing 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy 4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Symptomatic Therapy: Antipsychotics, Antidepressants, Mood Stabilizers, Muscle Relaxants 2) By Disease-Modifying Therapy: Gene Silencing Therapies, Neuroprotective Agents 3) By Other Treatment Types: Physical Therapy, Occupational Therapy, Speech Therapy

What Is The Driver Of The Huntington's Disease Market?

The rising prevalence of neurological disorders is expected to propel the growth of the huntington's disease market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, leading to symptoms such as movement, coordination, sensory, or cognitive impairments. The increase in neurological disorders can be attributed to factors such as aging populations, environmental toxins, lifestyle changes, improved diagnostic capabilities, and genetic predispositions, which help detect and identify more cases. Huntington's disease is a neurodegenerative disorder caused by a genetic mutation, leading to motor dysfunction, cognitive decline, and psychiatric symptoms, progressively worsening over time. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, an estimated 6.7 million Americans aged 65 and older currently have Alzheimer's dementia. Without medical breakthroughs to prevent, slow, or cure the disease, this number could rise to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is driving the growth of the huntington's disease industry.

Key Players In The Global Huntington's Disease Market

Major companies operating in the huntington's disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA.

Global Huntington's Disease Market Trends and Insights

Major companies operating in the huntington's disease market are focusing on developing innovative solutions, such as oral small molecule drugs to treat symptoms and slow disease progression. An oral small molecule drug is a low-molecular-weight compound that can be administered orally and is designed to interact with biological targets, such as proteins or enzymes, to treat diseases. For instance, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (USFDA) for its PTC518 program aimed at treating Huntington's disease. This designation is intended for therapies that address significant unmet medical needs, highlighting the potential of PTC518 as a disease-modifying treatment for patients suffering from this genetic disorder.

What Are Latest Mergers And Acquisitions In The Huntington's Disease Market?

In December 2024, PTC Therapeutics, Inc., a US-based biopharmaceutical company, partnered with Novartis AG to accelerate the development of PTC518 as an innovative oral treatment for Huntington's disease. Novartis AG is a Switzerland-based pharmaceutical company that specializes in providing branaplam (LMI070) for huntington's disease treatment.

Regional Outlook

North America was the largest region in the huntington's disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington's disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the huntington's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Huntington's Disease Market?

The huntington's disease market consists of revenues earned by entities by providing services such as medical management, psychological and social support, and physical, occupational, and speech therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The Huntington's disease market also includes sales of tetrabenazine, deutetrabenazine, and antidepressants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Huntington's Disease Market Report 2026?

The huntington's disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the huntington's disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.